DryShips Inc. (DRYS) Financials Nov 20, 2014, 6:17
DryShips Inc. (DRYS) Financials Nov 20, 2014, 6:17 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for DryShips Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 819.83M 859.75M 1.08B 1.21B 1.49B
Cost of Goods Sold (COGS) incl. D&A 426.98M 410.94M 672.61M 1.02B 1.07B
COGS excluding D&A 230.67M 218.05M 398.33M 679.73M 712.98M
Depreciation & Amortization Expense 196.31M 192.89M 274.28M 335.46M 357.37M
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 392.86M 448.81M 405.05M 194.95M 421.67M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 92.97M 87.28M 114.28M 145.94M 184.72M
Research & Development 0 0 0 0 0
Other SG&A 92.97M 87.28M 114.28M 145.94M 184.72M
Other Operating Expense 259.46M 0 0 41.34M 0
Unusual Expense (21.58M) 124.09M 207.43M 54.07M 73M
EBIT after Unusual Expense 21.58M (124.09M) (207.43M) (54.07M) (73M)
Non Operating Income/Expense (8.33M) (27.82M) (39.75M) (14.5M) (55.25M)
Non-Operating Interest Income 10.41M 21.87M 16.58M 4.2M 12.5M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 63.33M 20.59M 80.02M 187.94M 274.63M
Gross Interest Expense 94.72M 99.04M 156.09M 246.91M 344.35M
Interest Capitalized 31.38M 78.45M 76.07M 58.97M 69.71M
Pretax Income 766,000 210.89M (19.86M) (244.64M) (153.44M)
Income Tax 12.8M 20.44M 27.43M 43.96M 44.59M
Income Tax - Current Domestic 12.8M 20.23M 27.64M 43.96M 44.59M
Income Tax - Current Foreign - - - 0 0
Income Tax - Deferred Domestic 0 209,000 (209,000) 0 0
Income Tax - Deferred Foreign 0 - - 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 (56,000)
Consolidated Net Income (12.03M) 190.45M (47.29M) (288.59M) (198.08M)
Minority Interest Expense 7.18M 2.12M 22.84M (41.82M) 25.07M
Net Income (19.21M) 188.33M (70.13M) (246.78M) (223.15M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (19.21M) 188.33M (70.13M) (246.78M) (223.15M)
Preferred Dividends 7.5M 13.62M 4.47M 0 0
Net Income Available to Common (26.71M) 174.7M (74.59M) (246.78M) (223.15M)
EPS (Basic) (0.13) 0.64 (0.21) (0.65) (0.58)
Basic Shares Outstanding 209.33M 268.86M 355.14M 380.16M 384.06M
EPS (Diluted) (0.13) 0.61 (0.21) (0.65) (0.58)
Diluted Shares Outstanding 209.33M 305.43M 355.14M 380.16M 384.06M
EBITDA 236.74M 554.42M 565.05M 343.13M 594.32M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
d -->
Top 5 Most Recently Viewed Articles
Tackling Canada's Housing Crisis Canada is actively working to combat its housing crisis, with significant measures aimed at helping those who are homeless. While there’s a sense of hope in the air, the presence of encampments underscores the immediate need for long-lasting solutions. The federal government is stepping up its efforts, showing a dedicated resolve to...
Continue Reading
Rigetti Computing Announces Third Quarter Financial Results Rigetti Computing, Inc. (Nasdaq: RGTI), recognized as a leader in hybrid quantum-classical computing, has exciting news regarding its financial performance. The company is set to release its financial results for the third quarter of 2024 on a specified date, marking an important moment for stakeholders and...
Continue Reading
Solid Q3 Performance by Novartis In a significant announcement, Novartis reported an impressive growth in net sales and core operating income for the third quarter. During this period, the company's net sales reached USD 13.9 billion, reflecting a growth of 7% on a constant currency basis and an 8% increase in USD terms. Core operating income showed a similar trajectory,...
Continue Reading
Forestar Group Inc. to Announce First Quarter Earnings Forestar Group Inc. (NYSE: FOR) is preparing to share key financial results for its first quarter, marking the end of December 2024. This eagerly awaited announcement will take place shortly before the markets open on the designated day. Shareholders and interested parties will have the opportunity to hear about the...
Continue Reading
ImCheck Therapeutics Secures EMA Orphan Drug Designation ImCheck Therapeutics has exciting news as it recently announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to ICT01, its flagship treatment aimed at addressing acute myeloid leukemia (AML). This development, coming shortly after a similar designation from the U.S. FDA,...
Continue Reading